His career in the biopharmaceutical industry spans 20 years
Kemwell Biopharma, a global contract development and manufacturing services provider headquartered in Bangalore, India, has appointed Siddharth Advant as President of its Biopharmaceutical Services.
In his 20-year career, Advant has held a variety of leadership positions across the biopharmaceutical industry. He is joining Kemwell from ImClone Systems (a subsidiary of Eli Lilly) where he was Associate VP, CMC Project Management.
Prior to ImClone, Advant was the Head of Tunnell Consulting's West Coast Office. He has also worked for Diosynth Biotechnology as a Director, heading three primary areas: Project Management & Business Alliances, Technology Transfer & Clinical Operations, and Pharmaceutical Sciences & Stability. In these positions, he was responsible for technical and financial execution of customer projects, development and implementation of technology transfer programmes, as well as building and managing an analytical, formulation and cGMP testing laboratory. He has also worked as a scientist in the pharmaceutical development division at Protein Design Labs and as a programme manager for BioReliance, where he supervised a cGMP/GLP compliant formulation development business.